変性椎間板疾患(Degenerative Disc Disease):治療薬パイプラインレビュー

◆英語タイトル:Degenerative Disc Disease - Pipeline Review, H2 2018
◆商品コード:GMDHC10637IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年7月17日
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Degenerative Disc Disease – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease – Pipeline Review, H2 2018, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 4 and 3 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease – Overview
Degenerative Disc Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Degenerative Disc Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease – Companies Involved in Therapeutics Development
AnGes Inc
Biopharm GmbH
BioRestorative Therapies Inc
Bone Therapeutics SA
DiscGenics Inc
Kolon TissueGene Inc
Osiris Therapeutics Inc
Samumed LLC
U.S. Stem Cell Inc
Yuhan Corp
Degenerative Disc Disease – Drug Profiles
AdipoCell – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLOB – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BRTX-100 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTG-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTICR-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-04690 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Degenerative Disc Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-D – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-0002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-14618 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Degenerative Disc Disease – Dormant Projects
Degenerative Disc Disease – Product Development Milestones
Featured News & Press Releases
Jun 11, 2018: BioRestorative Therapies Reports Positive Findings from Independent Review of its BRTX-100 Program
May 31, 2018: Samumed to Present Data on SM04690 at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 30, 2018: DiscGenics: New Cell Therapy Could Help Millions Suffering from Back Pain
May 07, 2018: BioRestorative Therapies Appoints Wayne J. Olan as Clinical Director of Regenerative Disc/Spine Program
May 03, 2018: CTI Clinical Trial and Consulting Services Announces Collaboration with DiscGenics on First-In-Human Trial of Cell Therapy IDCT for Degenerative Disc Disease
Apr 26, 2018: DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease
Mar 22, 2018: DiscGenics Presents Promising Preclinical Study Results at ORS 2018
Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
Feb 15, 2018: Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
Jan 22, 2018: BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development
Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product
Dec 18, 2017: Samumed Doses First Patient in Phase I Trial of SM04690 for Treatment of Degenerative Disc Disease
Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell
Oct 05, 2017: BioRestorative Therapies Announces Published Study of Licensed Technology to Treat Lumbar Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Degenerative Disc Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Degenerative Disc Disease - Pipeline by AnGes Inc, H2 2018
Degenerative Disc Disease - Pipeline by Biopharm GmbH, H2 2018
Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H2 2018
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2018
Degenerative Disc Disease - Pipeline by DiscGenics Inc, H2 2018
Degenerative Disc Disease - Pipeline by Kolon TissueGene Inc, H2 2018
Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H2 2018
Degenerative Disc Disease - Pipeline by Samumed LLC, H2 2018
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H2 2018
Degenerative Disc Disease - Pipeline by Yuhan Corp, H2 2018
Degenerative Disc Disease - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Degenerative Disc Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[変性椎間板疾患(Degenerative Disc Disease):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆